Calcilytix
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Website
www.calcilytix.comRevenue
<$5 MillionIndustry
About Calcilytix
BridgeBio Pharma is dedicated to improving the lives of individuals with Autosomal Dominant Hypocalcemia Type 1 (ADH1) through the development of Encaleret, an investigational oral treatment targeting calcium-sensing receptor gene. ADH1 is a common genetic condition characterized by hypoparathyroidism caused by gain-of-function variants in the CASR. Encaleret is being developed in partnership with BridgeBio affiliate Calcilytix Therapeutics, aiming to address the physiological imbalances associated with ADH1.Explore more
Calcilytix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Calcilytix
Compare insights from companies similar to Calcilytix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Calcilytix Tech Stack
A closer look at the technologies used by Calcilytix
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Calcilytix
Sign Up For FreeTo access detailed company insights
BridgeBio Pharma is dedicated to improving the lives of individuals with Autosomal Dominant Hypocalcemia Type 1 (ADH1) through the development of Encaleret, an investigational oral treatment targeting calcium-sensing receptor gene. ADH1 is a common genetic condition characterized by hypoparathyroidism caused by gain-of-function variants in the CASR... Read More
